2026-04-13T01:18:42Zhttps://recercat.cat/oai/requestoai:recercat.cat:2445/663802025-12-05T09:21:35Zcom_2072_1057col_2072_478799col_2072_478917
RECERCAT
author
Chen, Fred K.
author
McLenachan, Samuel
author
Edel, Michael John
author
Da Cruz, Lyndon
author
Coffey, Peter J.
author
Mackey, David A.
2015-07-16T08:28:21Z2015-07-16T08:28:21Z2014-12-192015-07-16T08:28:21Z
For many decades, we have relied on immortalised retinal cell lines, histology of enucleated human eyes, animal models, clinical observation, genetic studies and human clinical trials to learn more about the pathogenesis of retinal diseases and explore treatment options. The recent availability of patient-specific induced pluripotent stem cells (iPSC) for deriving retinal lineages has added a powerful alternative tool for discovering new disease-causing mutations, studying genotype-phenotype relationships, performing therapeutics-toxicity screening and developing personalised cell therapy. This review article provides a clinical perspective on the current and potential benefits of iPSC for managing the most common blinding diseases of the eye: inherited retinal diseases and age-related macular degeneration.
cc-by (c) Chen, Fred Kuanfu et al., 2014 http://creativecommons.org/licenses/by/3.0/es info:eu-repo/semantics/openAccess
Cèl·lules mare
Malalties de la retina
Degeneració (Patologia)
Genètica molecular
Trasplantament d'òrgans
Stem cells
Retinal diseases
Degeneration (Pathology)
Molecular genetics
Transplantation of organs
iPS Cells for Modelling and Treatment of Retinal Diseases
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion